Abstract:Overexpression of the MYC oncogene, encoding c-MYC protein, contributes to the pathogenesis and drug resistance of acute myeloid leukemia (AML) and many other hematopoietic malignancies. Although standard chemotherapy has predominated in AML therapy over the past five decades, the clinical outcomes and patient response to treatment remain suboptimal. Deeper insight into the molecular basis of this disease should facilitate the development of novel therapeutics targeting specific molecules and pathways that are dysregulated in AML, including fms-like tyrosine kinase 3 (FLT3) gene mutation and cluster of differentiation 33 (CD33) protein expression. Elevated expression of c-MYC is one of the molecular features of AML that determines the clinical prognosis in patients. Increased expression of c-MYC is also one of the cytogenetic characteristics of drug resistance in AML. However, direct targeting of c-MYC has been challenging due to its lack of binding sites for small molecules. In this review, we focused on the mechanisms involving the bromodomain and extra-terminal (BET) and cyclin-dependent kinase 9 (CDK9) proteins, phosphoinositide-Akt-mammalian target of rapamycin (PI3K/AKT/mTOR) and Janus kinase-signal transduction and activation of transcription (JAK/STAT) pathways, as well as various inflammatory cytokines, as an indirect means of regulating MYC overexpression in AML. Furthermore, we highlight Food and Drug Administration (FDA)-approved drugs for AML, and the results of preclinical and clinical studies on novel agents that have been or are currently being tested for efficacy and tolerability in AML therapy. Overall, this review summarizes our current knowledge of the molecular processes that promote leukemogenesis, as well as the various agents that intervene in specific pathways and directly or indirectly modulate c-MYC to disrupt AML pathogenesis and drug resistance.

Phospho-eIF4E: a New Target for Acute Myeloid Leukemia.

Elevated Nuclear Phospho-Eif4e Body Levels Are Associated with Tumor Progression and Poor Prognosis for Acute Myeloid Leukemia

Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue.

Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia

Small-Molecule Inhibitors Targeting Eif4a in Leukemia

Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues.

Translational Regulator Eif2α in Tumor

Eukaryotic translation initiation factor 4A1 in the pathogenesis and treatment of cancers

Expression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers

The eukaryotic translation initiation factor eIF4E reprograms alternative splicing

Research progress in relation between phosphorylation of eIF4E and tumor

Regulation of Eukaryotic Translation Initiation Factor 4E as a Potential Anticancer Strategy

Overexpression of eIF4E gene in acute myeloid leukemia and its relation with disease progression]

Targeting Translation: Eif4e As an Emerging Anticancer Drug Target.

Dissecting Eif4e Action In Tumorigenesis

Targeting Transcription Factor SALL4 in Acute Myeloid Leukemia by Interrupting Its Interaction with an Epigenetic Complex.

The Eef1a Protein in Cancer: Clinical Significance, Oncogenic Mechanisms, and Targeted Therapeutic Strategies

eIF3a: A new anticancer drug target in the eIF family.

The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled

eIF4E S209 phosphorylation licenses Myc-and stress-driven oncogenesis

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia